When will we have a clone? An industry perspective on the typical CLD timeline.
CHO
CLD
Chinese hamster ovary
biologics
cell line development
risk
timeline
Journal
Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
revised:
07
02
2024
received:
01
12
2023
accepted:
14
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Cell line development (CLD) represents a complex but highly critical process during the development of a biological drug. To shed light on this crucial workflow, a team of BioPhorum members (authors) has developed and executed surveys focused on the activities and effort involved in a typical CLD campaign. An average of 27 members from different companies that participate in the BioPhorum CLD working group answered surveys covering three distinguishable stages of a standard CLD process: (1) Pre-transfection, including vector design and construction; (2) Transfection, spanning the initial introduction of vector into cells and subsequent selection and analysis of the pools; and (3) Single Cell Cloning and Lead Clone Selection, comprising methods of isolating single cells and confirming clonal origin, subsequent expansion and screening processes, and methods for identifying and banking lead clones. The surveys were very extensive, including a total of 341 questions split between antibody and complex molecule CLD processes. In this survey review, the authors interpret and highlight responses for antibody development and, where relevant, contrast complex molecule development challenges to provide a comprehensive industry perspective on the typical time and effort required to develop a CHO production cell line.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3449Informations de copyright
© 2024 The Authors. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Références
Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36:1137-1145.
Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. doi:10.1080/19420862.2021.2014296
Bailly M, Mieczkowski C, Juan V, et al. Predicting antibody developability profiles through early stage discovery screening. MAbs. 2020;12(1):1743053. doi:10.1080/19420862.2020.1743053
Jayapal KP, Wlaschin KF, Hu W-S, Yap MGS. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog. 2007;103:40-47.
Reinhart D, Damjanovic L, Kaisermayer C, et al. Bioprocessing of recombinant CHO-K1, CHO-DG44, and CHO-S: CHO expression hosts favor either mAb production or biomass synthesis. Biotechnol J. 2019;14:1700686. doi:10.1002/biot.201700686
Li Z-M, Fan Z-L, Wang X-Y, Wang T-Y. Factors affecting the expression of recombinant protein and improvement strategies in Chinese hamster ovary cells. Front Bioeng Biotechnol. 2022;10:1-12.
Bolisetty P, Tremmel g, Xu S, Khetan A. Enabling speed to clinic for monoclonal antibody programs using pool of clones for IND-enabling toxicity studies. MAbs. 2020;12(1):1763727. doi:10.1080/19420862.2020.1763727
Kelly B. Developing therapeutic monoclonal antibodies at pandemic space. Nat Biotechnol. 2020;38:540-545.
Higgins MF, Abu-Absi N, Gontarz E, et al. Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: a multi-company view from the biopharmaceutical industry. Biotechnol Prog. 2023;39:e3321. doi:10.1002/btpr.3321
Agostinetto R, Rossi M, Dawson J, et al. Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools. Biotechnol Bioeng. 2022;119(2):663-666.
Schmieder V, Fieder J, Drerup R, et al. Towards maximum acceleration of monoclonal antibody development: leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool. J Biotechnol. 2022;10(349):53-64.
ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products - Step 5. https://www.ema.europa.eu/documents/scientific-guideline/ich-q-5-d-derivation-characterisation-cell-substrates-used-production-biotechnological/biological-products-step-5_en.pdf
Frye C, Deshpande R, Estes S, et al. Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines. Biologicals. 2016;44(2):117-122.
Welch JT, Arden NS. Considering “clonality”: a regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. Biologicals. 2019;62:16-21.
Dhulipala P, Liu M, Beatty S, et al. Differential cell culture media for single-cell cloning requirements of CHO-S and CHO DG44 cells. BioProcess Int. 2011;9(11):44-45.
Lim UM, Yap MGS, Lim YP, Goh L-T, Ng SK. Identification of autocrine growth factors secreted by CHO cells for applications in single-cell cloning media. J Proteome Res. 2013;12:3496-3510.
Bauer J, Mathias S, Kube S, et al. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. MAbs. 2020;12(1):1787121. doi:10.1080/19420862.2020.1787121